AstraZeneca Pharma India Limited

Regd. Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore 560 045

Statement of unaudited financial results for the quarter and nine months ended 31 December 2023

Rs in lakhs except for earnings per share data

Sl No.	Particulars	3 months ended 31/12/2023	Previous 3 months ended 30/09/2023	Corresponding 3 months ended in the previous year 31/12/2022	9 months ended 31/12/2023	Corresponding 9 months ended in the previous year 31/12/2022	Year ended 31/03/2023
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	**Income**						
	a) Revenue from operations	30,578.90	31,107.16	24,980.85	91,232.74	71,826.73	100,297.08
	b) Other income	965.99	837.29	719.61	2,613.65	1,810.46	2,610.18
	Total income	**31,544.89**	**31,944.45**	**25,700.46**	**93,846.39**	**73,637.19**	**102,907.26**
2	**Expenses**						
	(a) Cost of materials consumed	3,751.88	3,880.20	2,710.45	9,539.84	6,275.86	8,437.84
	(b) Purchase of stock-in-trade	18,153.37	13,994.44	7,424.49	42,432.76	22,074.42	32,445.69
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(7,076.10)	(5,661.69)	(988.24)	(13,871.91)	(2,215.81)	(4,885.80)
	(d) Employee benefit expense	6,323.36	6,526.60	6,268.42	18,347.44	19,224.28	25,910.26
	(e) Depreciation expense	370.46	367.39	413.23	1,117.64	1,201.11	1,626.00
	(f) Allowance for expected credit loss (net)	(3.09)	151.49	46.00	125.94	125.74	167.03
	(g) Selling, marketing and distribution expense	2,835.29	1,524.37	2,078.71	6,486.27	4,595.45	5,974.17
	(h) Other expenses	5,088.52	5,415.83	3,782.11	14,666.26	11,219.14	15,735.38
	(i) Finance costs	61.27	50.01	19.65	126.63	54.52	63.32
	Total expenses	**29,504.96**	**26,248.64**	**21,754.82**	**78,970.87**	**62,554.71**	**85,473.89**
3	**Profit before exceptional items and tax (1-2)**	**2,039.93**	**5,695.81**	**3,945.64**	**14,875.52**	**11,082.48**	**17,433.37**
4	Exceptional items (expense) / income (Refer Note 4 and 5)	-	1,642.63	-	1,642.63	-	(4,022.91)
5	**Profit before tax (3+4)**	**2,039.93**	**7,338.44**	**3,945.64**	**16,518.15**	**11,082.48**	**13,410.46**
6	**Tax expense**						
	- Current tax	465.34	1,591.44	984.57	3,803.48	2,992.07	3,830.25
	- Tax expense for prior years (Refer Note 5)	-	537.95	-	537.95	-	-
	- Deferred tax charge/ (credit)	(5.50)	(27.93)	30.63	(26.42)	(111.72)	(349.04)
	Total tax expense	**459.84**	**2,101.46**	**1,015.20**	**4,315.01**	**2,880.35**	**3,481.21**
7	**Profit after tax (5-6)**	**1,580.09**	**5,236.98**	**2,930.44**	**12,203.14**	**8,202.13**	**9,929.25**
8	**Other comprehensive income/(loss)**						
	A. Items that will not be reclassified to profit or loss						
	Re-measurement gains/(losses) on post employment benefit obligations	7.09	38.39	(36.31)	106.30	(70.61)	(349.35)
	Income tax effect on above	(1.78)	(9.66)	9.14	(26.75)	17.77	87.92
	Other comprehensive income/ (loss), net of income tax	**5.31**	**28.73**	**(27.17)**	**79.55**	**(52.84)**	**(261.43)**
	Total comprehensive income for the period (7+8)	**1,585.40**	**5,265.71**	**2,903.27**	**12,282.69**	**8,149.29**	**9,667.82**
9	**Paid-up equity share capital** (Face value of Rs 2/- per equity share)	**500.00**	**500.00**	**500.00**	**500.00**	**500.00**	**500.00**
10	Other Equity	-	-	-	-	-	58,368.83
11	**Earnings per equity share of Rs 2/- each (basic and diluted)**	**6.32**	**20.95**	**11.72**	**48.81**	**32.81**	**39.72**

Price Waterhouse & Co Chartered Accountants LLP
LLPIN AAC-4362
FRN 304026E/E300009
★ Bengaluru ★

AstraZeneca Pharma India Limited
Regd. Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore 560 045

Statement of unaudited financial results for the quarter and nine months ended 31 December 2023

Notes:

1. The financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (as amended) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
2. The Company has identified 'Healthcare Segment' as its only reportable segment in accordance with the requirements of Ind AS 108, 'Operating Segments'. Accordingly no segment information has been provided.
3. Consequent to Company's announcement to Stock exchange on 16 November 2023 on its intention to exit the manufacturing site in Bangalore in due course, the Company has started its search for a buyer who can also act as a Contract Manufacturing Organisation.
4. Exceptional items for the quarter and year ended 31 March 2023 consists of seperation cost amounting to Rs.1,910.32 lakhs and Voluntary Retirement Scheme expenses amounting to Rs.2,112.59 lakhs.
5. Exceptional items for the quarter ended 30 September 2023 consists of amount pertaining to certain previously disputed disclosed Transfer Pricing matters amounting to Rs.1642.63 lakhs.
6. This statement of financial results was reviewed and recommended by the Audit Commiltee of the Board and subsequently approved by the Board of Directors at their respective meetings held on 8 February 2024. The Statutory auditors of the Company have carried out a limited review of this statement of financial results for the quarter ended 31 December 2023.

By Order of the Board of Directors
For AstraZeneca Pharma India Limited

Place: Bengaluru
Date: 8 February 2024

Sanjeev Kumar Panchal
Managing Director

Price Waterhouse & Co Chartered Accountants LLP
LLPIN AAC-4362
FRN 304026E/E300009
★ Bengaluru ★